Chardan Capital Rates Tenax Therapeutics (TENX) buy

Analyst Gautam Chukka maintains a buy recommendation on Tenax Therapeutics with a $27 price target, a 108.82% upside from the current price.

By TradeTexts Research Desk · Published Jun 22, 2026, 9:01 AM EDT · Updated Jun 25, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Chardan Capital rated Tenax Therapeutics, Inc. ($TENX) "buy" with a $27 price target on June 22, 2026.

Since the rating, $TENX is up 10.2% after 1 week, up 20.7% after 1 month and down 88.9% to date (from the $12.25 close on Jun 22, 2026).

TENX Tenax Therapeutics, Inc.

$1.36 -87.69% year to date

Daily close · Oct 16, 2026

Key Points

Chardan Capital reiterated its buy rating on Tenax Therapeutics, Inc. (NasdaqCM: TENX) with a $27 price target on June 22, 2026.
Chardan Capital's $27 price target implies 108.82% upside from Tenax Therapeutics, Inc.'s ($TENX) current $12.93 share price.
The biotech firm trades around $12.93, sitting between its 52-week low of $1.31 and 52-week high of $19.40.
Wall Street currently tracks 9 analyst opinions for the company, showing a general buy recommendation key.

Get $TENX trade alerts by text

We text you when insiders, Congress or big funds trade $TENX. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Tenax Therapeutics, Inc. alert may contain errors. Disclosures

Chardan Capital Sticks with Its Outlook for Tenax Therapeutics

On June 22, 2026, Chardan Capital analyst Gautam Chukka reiterated a buy rating on Tenax Therapeutics, Inc. (NasdaqCM: TENX) while keeping a price target of $27. The update keeps the firm's stance steady on the clinical-stage drug developer as the stock trades in the public markets. The decision outlines the firm's view on the company's experimental therapies without shifting the projected valuation.

Tenax Therapeutics Stock Context and Moving Averages

Shares of Tenax Therapeutics changed hands around $12.93, positioning the equity well above its 52-week low of $1.31 and below its 52-week high of $19.40. The stock's 50-day moving average sits at $7.05, while the 200-day moving average stands at $11.55. The company carries a market capitalization of roughly $70.36 million alongside a beta of 0.823.

12-month forecast

$TENX price target

Tenax Therapeutics, Inc. daily closes and this analyst's $27 target. Not advice.

Recent Analyst Rating Updates for TENX

Coverage across Wall Street includes several recent notes from major financial firms. On August 31, 2026, Guggenheim downgraded the stock to a neutral rating with no target listed. Earlier in August, Chardan Capital adjusted its stance by downgrading the stock to a neutral rating and lowering its target to $5 from $27. Canaccord Genuity maintained a buy rating on August 11, 2026, while adjusting its target to $4 from $35. Guggenheim also maintained a buy rating on August 11 with a $4 target. Evercore ISI Group moved the stock to an in-line rating with a $5 target on August 11, and William Blair shifted to a market perform rating on August 10. Earlier in the summer, Chardan Capital maintained a buy rating at $27 on July 31, and Cantor Fitzgerald reiterated an overweight rating with a $35 target on July 29. Overall, the company holds 9 analyst opinions with a consensus buy recommendation key, a mean target price of $12.56, a high target of $36, and a low target of $4.

Inside Tenax Therapeutics and Its Pipeline Focus

Tenax Therapeutics operates as a development-stage pharmaceutical company focused on creating novel cardiopulmonary therapies in the United States. Its pipeline features treatments like levosimendan for pulmonary hypertension and imatinib for chronic myeloid leukemia. Headquartered in Chapel Hill, North Carolina, the small team of 14 employees works to advance clinical trials.

What to Watch Next for TENX

Investors will look toward upcoming clinical updates and the company's next earnings report scheduled for August 11, 2025. Market participants continue monitoring how shifting analyst targets impact share price momentum across the healthcare sector.